Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by PDT Partners LLC

PDT Partners LLC lowered its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 59.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,748 shares of the biotechnology company’s stock after selling 23,276 shares during the period. PDT Partners LLC’s holdings in Sarepta Therapeutics were worth $1,915,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Manchester Capital Management LLC increased its position in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in shares of Sarepta Therapeutics in the fourth quarter worth about $36,000. Steward Partners Investment Advisory LLC raised its stake in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 216 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $60.85 on Wednesday. The company has a market cap of $5.90 billion, a P/E ratio of 48.68 and a beta of 0.93. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a twelve month low of $48.01 and a twelve month high of $173.25. The company’s 50-day moving average price is $75.46 and its 200-day moving average price is $104.84.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on SRPT. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. HC Wainwright reissued a “neutral” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, April 16th. Morgan Stanley lowered their price target on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating on the stock in a report on Friday, April 11th. Piper Sandler reduced their price objective on Sarepta Therapeutics from $182.00 to $110.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $158.70.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.